ETAR (antiviral)

ETAR
Legal status
Legal status
Identifiers
  • (2R,3R,4S,5R)-2-(3-ethynyl-1,2,4-triazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
PubChem CID
Chemical and physical data
FormulaC9H11N3O4
Molar mass225.204 g·mol−1
3D model (JSmol)
  • C#CC1=NN(C=N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
  • InChI=1S/C9H11N3O4/c1-2-6-10-4-12(11-6)9-8(15)7(14)5(3-13)16-9/h1,4-5,7-9,13-15H,3H2/t5-,7-,8-,9-/m1/s1
  • Key:ZCYWFUPNZBYYLW-ZOQUXTDFSA-N

ETAR (1β-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole) is a nucleoside analogue which has antiviral effects, related to compounds such as EICAR. It shows broad spectrum antiviral action against viruses such as hantaviruses, flaviviruses and bunyaviruses.[1][2][3][4][5][6][7][8][9]

See also

References

  1. ↑ Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, et al. (July 2008). "Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus". Antiviral Research. 79 (1): 19–27. doi:10.1016/j.antiviral.2008.02.003. PMC 2692291. PMID 18394724.
  2. ↑ McDowell M, Gonzales SR, Kumarapperuma SC, Jeselnik M, Arterburn JB, Hanley KA (July 2010). "A novel nucleoside analog, 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro". Antiviral Research. 87 (1): 78–80. doi:10.1016/j.antiviral.2010.04.007. PMC 2892036. PMID 20416341.
  3. ↑ Gowen BB, Hickerson BT (March 2017). "Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies". Journal of Microbiology. 55 (3): 183–195. doi:10.1007/s12275-017-7029-8. PMID 28243938.
  4. ↑ Dheerasekara K, Sumathipala S, Muthugala R (2020). "Hantavirus Infections-Treatment and Prevention". Current Treatment Options in Infectious Diseases. 12 (4): 410–421. doi:10.1007/s40506-020-00236-3. PMC 7594967. PMID 33144850.
  5. ↑ El-Sebaey SA. Recent Advances in 1,2,4-Triazole Scaffolds as Antiviral Agents. ChemistrySelect 2020; 5(37):11654-11680. doi:10.1002/slct.202002830
  6. ↑ Deng X, Tian S, Yu Z, Wang L, Liang R, Li Y, Xiang R, Jiang S, Ying T, Yu F. Development of small-molecule inhibitors against hantaviruses. Microbes and Infection 2020; 22(6-7): 272-277. doi:10.1007/s10593-021-02912-8
  7. ↑ Kataev VE, Garifullin BF (2021). "Antiviral nucleoside analogs". Chemistry of Heterocyclic Compounds. 57 (4): 326–341. doi:10.1007/s10593-021-02912-8. PMC 8118684. PMID 34007086.
  8. ↑ De A, Sarkar S, Majee A (2021). "Recent advances on heterocyclic compounds with antiviral properties". Chemistry of Heterocyclic Compounds. 57 (4): 410–416. doi:10.1007/s10593-021-02917-3. PMC 8113790. PMID 33994556.
  9. ↑ Khan A, Wahab S, Hong ST (February 2025). "Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches". Virology Journal. 22 (1) 26. doi:10.1186/s12985-025-02622-z. PMC 11792744. PMID 39905499.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.